Newsroom

Innovaccer Inc. today announced that it has acquired a 100% stake in Cured, a leading digital marketing and CRM platform for healthcare. This strategic move marks a significant milestone in Innovaccer’s commitment to revolutionize healthcare.

Vita Health, the first provider of clinically validated suicide prevention through innovative care management, announced today the close of a $22.5M Series A funding round.

In this episode of the CU Anschutz 360 podcast, Daniel LaBarbera, PhD, director of the Center for Drug Discovery, talks about harnessing technology and innovation to speed the development of new therapies.

Reimagine Care and CU Innovations announce a poster presentation at the prestigious 2023 American Society of Hematology (ASH) Annual Meeting and Exposition.

Sensorium Therapeutics (Sensorium) welcomed Alexandra (Sandra) Glucksmann, PhD, as CEO and President. Former CEO and Co-founder, Dick Simon, transitions to an advisory role while continuing to serve on the Board of Directors.

Q32 Bio Inc. and Homology Medicines, Inc., announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Tucson, AZ – September 19, 2023 – Ceria Therapeutics, Inc.(Ceria), an Arizona-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a third Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to the development of CTX-002 for the treatment of progressive inflammatory lung disorders, including Acute Lung Injuries (ALI), Acute Lung Failure (ARF), and Acute Respiratory Distress Syndrome (ARDS).

WALTHAM, Mass. and DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata. Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.